Entrada Therapeutics (TRDA)
(Real Time Quote from BATS)
$14.25 USD
-0.50 (-3.39%)
Updated Aug 5, 2024 10:26 AM ET
1-Strong Buy of 5 1
B Value A Growth B Momentum A VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 8/13/24 |
---|---|
Current Quarter | 0.65 |
EPS Last Quarter | 0.68 |
Last EPS Surprise | 278.95% |
ABR | 1.40 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -0.13 |
Next Year | -3.21 |
EPS (TTM) | 0.63 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 55.00M | 18.50M | 150.47M | 59.80M |
# of Estimates | 2 | 2 | 3 | 3 |
High Estimate | 75.00M | 30.00M | 162.30M | 75.00M |
Low Estimate | 35.00M | 7.00M | 139.10M | 48.00M |
Year ago Sales | 18.17M | 43.74M | 129.01M | 150.47M |
Year over Year Growth Est. | 202.70% | -57.70% | 16.63% | -60.26% |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | 0.65 | -0.64 | -0.13 | -3.21 |
# of Estimates | 3 | 3 | 3 | 3 |
Most Recent Consensus | -0.05 | -0.23 | -0.37 | -3.77 |
High Estimate | 1.23 | -0.23 | 0.26 | -2.21 |
Low Estimate | -0.05 | -0.84 | -0.37 | -3.77 |
Year ago EPS | -0.78 | 1.02 | -0.20 | -0.13 |
Year over Year Growth Est. | 183.33% | -162.75% | 35.00% | -2,371.79% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 1 | 1 | 1 | 1 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 0 | 0 | 0 | 0 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | 0.65 | -0.64 | -0.13 | -3.21 |
7 Days Ago | 0.65 | -0.64 | -0.13 | -3.21 |
30 Days Ago | 0.65 | -0.64 | -0.13 | -3.21 |
60 Days Ago | 0.65 | -0.65 | -0.14 | -3.44 |
90 Days Ago | -0.33 | -0.44 | -1.54 | -2.78 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | 0.65 | -0.64 | -0.13 | -3.21 |
Zacks Consensus Estimate | 0.65 | -0.64 | -0.13 | -3.21 |
Earnings ESP | 0.00% | 0.00% | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | 0.68 | -0.29 | 1.02 | -0.78 | NA |
Estimate | -0.38 | -0.07 | -0.55 | -0.43 | NA |
Difference | 1.06 | -0.22 | 1.57 | -0.35 | 0.52 |
Surprise | 278.95% | -314.29% | 285.45% | -81.40% | 42.18% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more